Novo Nordisk A/SNVONYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank21
3Y CAGR-68.5%
5Y CAGR-24.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-68.5%/yr
vs +58.6%/yr prior
5Y CAGR
-24.3%/yr
Recent deceleration
Acceleration
-127.2pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 0.73% |
| 2024 | 9.38% |
| 2023 | 21.53% |
| 2022 | 23.44% |
| 2021 | 11.31% |
| 2020 | 2.95% |
| 2019 | 7.56% |
| 2018 | 3.70% |
| 2017 | -0.66% |
| 2016 | 0.53% |